Recent clinical research reported the safety and feasibility of IL-1R antagonist (anakinra) in patients with PAH and RV failure, suggesting that IL-1 blockade may have the potential for treatment [100]. The gene discussed is IL1A; the disease is pulmonary arterial hypertension.